BG
CLDX icon

Bellevue Group’s Celldex Therapeutics CLDX Stock Holding History

Bellevue Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.7M Hold
1,200,000
– – 0.94% 30
2026
Q1 		$38.1M Sell
1,200,000
-2,417,669
-67% -$65.9M 0.91% 34
2025
Q4 		$98.3M Buy
3,617,669
+60,000
+2% +$1.58M 1.86% 17
2025
Q3 		$92M Buy
3,557,669
+250,100
+8% +$5.8M 1.91% 17
2025
Q2 		$67.3M Buy
3,307,569
+235,954
+8% +$4.59M 1.48% 20
2025
Q1 		$55.7M Hold
3,071,615
– – 1.25% 20
2024
Q4 		$77.6M Hold
3,071,615
– – 1.49% 20
2024
Q3 		$104M Buy
3,071,615
+100,000
+3% +$3.81M 1.69% 16
2024
Q2 		$110M Buy
2,971,615
+175,000
+6% +$6.6M 1.79% 17
2024
Q1 		$117M Buy
2,796,615
+380,319
+16% +$15.6M 1.79% 16
2023
Q4 		$95.8M Buy
2,416,296
+516,296
+27% +$15.2M 1.47% 17
2023
Q3 		$52.3M Buy
1,900,000
+100,000
+6% +$3.13M 0.84% 29
2023
Q2 		$61.1M Hold
1,800,000
– – 0.87% 33
2023
Q1 		$64.8M Hold
1,800,000
– – 0.94% 37
2022
Q4 		$80.2M Hold
1,800,000
– – 1.06% 27
2022
Q3 		$50.6M Buy
1,800,000
+875,000
+95% +$26.8M 0.73% 44
2022
Q2 		$24.9M Buy
+925,000
New +$26.9M 0.35% 77
2017
Q4 		– Sell
-10,667
Closed -$458K – 135
2017
Q3 		$458K Hold
10,667
– – 0.05% 126
2017
Q2 		$395K Hold
10,667
– – 0.05% 128
2017
Q1 		$578K Hold
10,667
– – 0.08% 119
2016
Q4 		$566K Hold
10,667
– – 0.12% 106
2016
Q3 		$646K Hold
10,667
– – 0.12% 112
2016
Q2 		$702K Hold
10,667
– – 0.13% 105
2016
Q1 		$605K Buy
+10,667
New +$1.2M 0.11% 108

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bellevue Group's CLDX Position: Q2 2026 in Review

Bellevue Group held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 1,200,000 shares worth $44.7M. The position accounts for 0.94% of the portfolio, ranked #30.

Bellevue Group first reported a position in CLDX in Q1 2016 and has held it in 24 quarters since. The position peaked at $117M in Q1 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Bellevue Group held 1,200,000 shares of Celldex Therapeutics worth $44.7M as of Q2 2026.
  • Bellevue Group left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up 0.94% of Bellevue Group's portfolio in Q2 2026, its #30 holding.
  • Bellevue Group first reported a position in Celldex Therapeutics in Q1 2016 and has held it in 24 quarters since.
  • Bellevue Group's Celldex Therapeutics position peaked at $117M in Q1 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.